Gene · 432
Papers2,727
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,727
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Artificial intelligence-augmented smart grid architecture for cyber intrusion detection and mitigation in electric vehicle charging infrastructure. | Sci Rep | 2025 | 40594097 | PubTator, text mining | PubMed |
| Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy. | Nat Commun | 2025 | 40593574 | PubTator, text mining | PubMed |
| Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids. | Biomed Pharmacother | 2025 | 40580877 | PubTator, text mining | PubMed |
| Emerging Concepts of Targeted Protein Degrader Technologies via Lysosomal Pathways. | Int J Mol Sci | 2025 | 40565046 | PubTator, text mining | PubMed |
| Characterizing the Membrane Assembly of ASGPR Related to Mediated Endocytosis Using TriGalNAc-Probe-Based Super-Resolution Imaging. | JACS Au | 2025 | 40443899 | PubTator, text mining | PubMed |
| A BODIPY-tagged trivalent glycocluster for receptor-targeting fluorescence imaging of live cells. | Chem Sci | 2025 | 40438166 | PubTator, text mining | PubMed |
| A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1. | Int J Mol Sci | 2025 | 40429734 | PubTator, text mining | PubMed |
| ASGR1 inhibitors, inflammation, and heart failure: A Mendelian randomization analysis. | Lipids | 2025 | 40391737 | PubTator, text mining | PubMed |
| Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen. | Mol Ther Nucleic Acids | 2025 | 40385635 | PubTator, text mining | PubMed |
| Carboxylesterase-activated hepatocyte-targeting fluorescent probe for drug-induced liver injury diagnosis. | Bioorg Chem | 2025 | 40381462 | PubTator, text mining | PubMed |
| Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases. | Eur J Endocrinol | 2025 | 40378187 | PubTator, text mining | PubMed |
| Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity. | Sci Rep | 2025 | 40374718 | PubTator, text mining | PubMed |
| Phase I Study of 68Ga-NOTA-HL for PET/CT Imaging of Hepatic Asialoglycoprotein Receptors in Healthy Volunteers. | J Nucl Med Technol | 2025 | 40345823 | PubTator, text mining | PubMed |
| MiR-122-5p inhibits the epithelial mesenchymal transition of liver cancer cells by inducing hiPSCs to differentiate into hepatocyte-like cells. | Eur J Histochem | 2025 | 40336362 | PubTator, text mining | PubMed |
| Cross-sectional, interventional, and causal investigation of insulin sensitivity using plasma proteomics in diverse populations. | Metabolism | 2025 | 40221021 | PubTator, text mining | PubMed |
| Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications. | Nanomaterials (Basel) | 2025 | 40214585 | PubTator, text mining | PubMed |
| Mesoporous silica-glycopolymer hybrid nanoparticles for dual targeted chemotherapy and gene therapy to liver cancer cells. | Int J Pharm | 2025 | 40187702 | PubTator, text mining | PubMed |
| TransTACs: Transforming antibodies into targeted protein degraders. | Acta Pharm Sin B | 2025 | 40177569 | PubTator, text mining | PubMed |
| Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. | Expert Rev Mol Med | 2025 | 40160040 | PubTator, text mining | PubMed |
| The Progress and Evolving Trends in Nucleic-Acid-Based Therapies. | Biomolecules | 2025 | 40149911 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/432/papers?page=8